CA
NZ
UK
AU
IND
US
Weave Communications, Inc. filed a current report on Form 8-K on August 18, 2026, disclosing the execution of an Agreement and Plan of Merger with Willow Parent, LLC and Willow Merger Sub, Inc., both affiliates of Francisco Partners Management, L.P.
Arxis, Inc. (NASDAQ:ARXS) filed a Form 8-K on August 18, 2026, disclosing the August 17, 2026, completion of its acquisition of Omnetics Connector Corporation through a merger agreement originally announced on May 29, 2026.
Dream Finders Homes, Inc. filed a Form 8-K on August 18, 2026, under Item 7.01 Regulation FD Disclosure, providing pro forma capitalization details expected immediately following its planned merger with Beazer Homes USA, Inc.
BioMarin Pharmaceutical Inc. filed a current report on Form 8-K on August 18, 2026, disclosing that it entered into a Share Purchase Agreement on August 17, 2026, to acquire Alesta Therapeutics B.V., a private Dutch rare disease company, for an upfront payment of $275 …
GE HealthCare Technologies Inc. filed a current report on August 18, 2026, disclosing that its Board of Directors appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026.
Privia Health Group, Inc. filed a Form 8-K on August 18, 2026, disclosing that its Board of Directors elected Opella Ernest, M.D. as a Class III director, effective September 1, 2026.
Virgin Galactic Holdings, Inc. filed a current report on August 18, 2026, disclosing that a U.S. federal court granted final approval of the settlement of two consolidated derivative lawsuits against the company.
Xylem Inc. filed a Form 8-K with the SEC on August 18, 2026, disclosing the resignation of Chief Financial Officer William K. Grogan and the appointment of Andrea van der Berg as his successor, effective September 1, 2026.
Amylyx Pharmaceuticals, Inc. filed a Form 8-K on August 18, 2026, disclosing positive topline results from its Phase 3 LUCIDITY clinical trial evaluating avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
Amylyx Pharmaceuticals, Inc. filed a Form 8-K on August 18, 2026, disclosing that it hosted an investor and analyst conference call on that date to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating avexitide in participants with post-bariatric hypoglycemia following …
Please wait processing your request...